Prosonix Elects Dr Ken Cunningham as Non-executive Chairman
News Dec 05, 2012
Prosonix has announced the election of Dr Ken Cunningham as Non-executive Chairman. He replaces Dr Jim Philips, who has been Chairman of the Company since 2007, and is retiring from the Board of Directors.
Dr Cunningham was elected to the Board of Prosonix as a Non-executive Director in September 2011, and is also Chair of Prosonix’s Scientific Advisory Board.
He has over 20 years' experience in the pharmaceutical industry with a strong focus in recent years on respiratory drug development and drug delivery.
He is Chairman of PolyTherics Ltd and until August 2010 was CEO of Skyepharma plc. Before that he was Chief Executive Officer of Arakis Ltd, Vice-President European Affairs at Alza Corporation and Vice-President Clinical Development at Sequus Inc.
He holds a medical degree from St Mary's, Imperial College, London University.
Dr Ken Cunningham, said: “Over recent years, Prosonix’s particle engineering technology has repeatedly demonstrated its exciting potential for optimizing many of the respiratory medicines currently used in the treatment of asthma and COPD. During this period, the Company has made a successful transition from applying its technology to third party compounds to using it to build its own pipeline of directly substitutable generic and proprietary inhaled drugs based on improved versions of known drugs in simple, cost effective and already approved devices. I would like to take this opportunity, on behalf of the Prosonix Board, to thank Dr Phillips for his important contribution as Chairman during this period of transformation. I am very pleased to continue his work and help Prosonix deliver its corporate and clinical strategy, which is focused on building further value from the Company’s portfolio of inhaled drug candidates.”
Dr Jim Phillips, said: “After five years chairing Prosonix and helping shape it into the inhalation product-focused company it is today, I am delighted to hand over Chairmanship to Dr Ken Cunningham to bring his respiratory experience to bear towards the Company's future success.”
Concept Life Sciences and Alderley Analytical Partner to provide Bioanalytical and DMPK ServicesNews
Companies announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.READ MORE
Arrow Poison Potential Male Birth ControlNews
Women have many options for oral contraceptives that are safe, effective and reversible, but despite decades of research, men have none. Now, scientists report a rat study that shows they finally have a good lead for a male birth control pill. It's based on ouabain, a plant extract that African warriors and hunters traditionally used as a heart-stopping poison on their arrows.READ MORE